Immunomedics Announces New Data for IMMU-132 at Investor R&D Day
Jan 18, 2017 14:01 pm UTC| Business
-- IMMU-132 Provides Opportunity for Significant Near-Term Value Creation -- -- Submission for Accelerated Approval Application to FDA for Patients with Metastatic TNBC Remains on Track for mid-2017 -- -- Company...
PharmaCyte Biotech to Hold Shareholder Call
Jan 18, 2017 14:01 pm UTC| Business
LAGUNA HILLS, Calif., Jan. 18, 2017 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell...
PharmaCyte Biotech to Hold Shareholder Call
Jan 18, 2017 14:01 pm UTC| Business
LAGUNA HILLS, Calif., Jan. 18, 2017 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell...
Jan 18, 2017 14:01 pm UTC| Business
NEW YORK, Jan. 18, 2017 -- Hunt Mortgage Partners, LLC, a wholly owned subsidiary of Hunt Mortgage Group and a leader in financing commercial real estate throughout the United States, today announced it provided...
Jan 18, 2017 14:01 pm UTC| Business
NEW YORK, Jan. 18, 2017 -- Hunt Mortgage Partners, LLC, a wholly owned subsidiary of Hunt Mortgage Group and a leader in financing commercial real estate throughout the United States, today announced it provided...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
Jan 18, 2017 14:01 pm UTC| Business
NEW YORK, Jan. 18, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
Jan 18, 2017 14:01 pm UTC| Business
NEW YORK, Jan. 18, 2017 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the...